Spironolactone in Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 250 participants.

Also called NCT02673463

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 250 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02673463
Other papers using this trial's data
  • Spironolactone in Atrial Fibrillation With Preserved Cardiac Fraction: The IMPRESS-AF Trial Journal of the American Heart Association, 2020-09-15 DOI, PubMed 32909497, PMC7726985 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United Kingdom (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02673463. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2018-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Spironolactone in Atrial Fibrillation
Acronym
IMPRESS-AF
Intervention (Drug)
Spironolactone
Intervention (Drug)
Placebo
Lead sponsor
University of Birmingham (class: other)

Record details

Record id
cardio:ct-nct02673463
Content hash
57dc43a2911fa982481a3143e3d61f46727fc2eefdb2ca0e89cc31dc0a3ccfe8